research
Huang lab applies a multidisciplinary approach to elucidate the mechanisms and functions of epigenetic modifications including methylation and acetylation to develop novel therapeutic agents for cancer, metabolic, infectious, and neurodegenerative diseases; rational designs and synthesize selective and potent inhibitors for methyltransferases and acetyltransferases; develop HTS assay and efficiently create compounded libraries to screen lead compounds.
research projects
Project 1: Targeting Methyltransferases (NTMTs, NNMT, and PRMTs) to discover new drugs
Available Methyltransferase Inhibitors:
Protein n-terminal MTase 1/2 (NTMT1/2): DC541 (acs med chem letts); GD562; GD433 (pmid: 36634151)
Nicotinamide N-MTase (NNMT): LL320 (pmid: 31724854); II399 (pmid: 35134268); II559; II802; II630
Project 2: Targeting Protein α-N-terminal Acetylation
Available Protein N-terminal acetyltransferase (NAT) inhibitors
NatD: YD612 (pmid:34110812)
Available Methyltransferase Inhibitors:
Protein n-terminal MTase 1/2 (NTMT1/2): DC541 (acs med chem letts); GD562; GD433 (pmid: 36634151)
Nicotinamide N-MTase (NNMT): LL320 (pmid: 31724854); II399 (pmid: 35134268); II559; II802; II630
Project 2: Targeting Protein α-N-terminal Acetylation
Available Protein N-terminal acetyltransferase (NAT) inhibitors
NatD: YD612 (pmid:34110812)
collaboration
Huang Lab is always open to collaborative opportunities. If you are interested, please contact Dr. Rong Huang at huang-r at purdue dot edu.
